Details

Autor(en) / Beteiligte

• Delaunay, Myriam
• Cadranel, Jacques
• Lusque, Amélie
• Meyer, Nicolas
• Gounant, Valérie
• Moro-Sibilot, Denis
• Michot, Jean-Marie
• Raimbourg, Judith
• Girard, Nicolas
• Guisier, Florian
• Planchard, David
• Metivier, Anne-Cécile
• Tomasini, Pascale
• Dansin, Eric
• Pérol, Maurice
• Campana, Marion
• Gautschi, Oliver
• Früh, Martin
• Fumet, Jean-David
• Audigier-Valette, Clarisse
• Couraud, Sébastien
• Dalle, Stéphane
• Leccia, Marie-Thérèse
• Jaffro, Marion
• Collot, Samia
• Prévot, Grégoire
• Milia, Julie
• Mazieres, Julien

Titel

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Ist Teil von

• The European respiratory journal, 2017-08, Vol.50 (2)

Ort / Verlag

England

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event.Between December 2015 and April 2016, we conducted a retrospective study in centres experienced in ICI use. We report the main features of ICI-ILD with a focus on clinical presentation, radiological patterns and therapeutic strategies.We identified 64 (3.5%) out of 1826 cancer patients with ICI-ILD. Patients mainly received programmed cell death-1 inhibitors. ILD usually occurred in males, and former or current smokers, with a median age of 59 years. We observed 65.6% grade 2/3 severity, 9.4% grade 4 severity and 9.4% fatal ILD. The median (range) time from initiation of immunotherapy to ILD was 2.3 (0.2-27.4) months. Onset tended to occur earlier in lung cancer melanoma: median 2.1 and 5.2 months, respectively (p=0.02). Ground-glass opacities (81.3%) were the predominant lesions, followed by consolidations (53.1%). Organising pneumonia (23.4%) and hypersensitivity pneumonitis (15.6%) were the most common patterns. Overall survival at 6 months was 58.1% (95% CI 37.7-73.8%).ICI-ILD often occurs early and displays suggestive radiological features. As there is no clearly identified risk factor, oncologists need to diagnose and adequately treat this adverse event.